Welcome to our dedicated page for Colgate Palmolive Co SEC filings (Ticker: CL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Colgate-Palmolive Company (NYSE: CL) SEC filings page on Stock Titan brings together the company’s regulatory disclosures, including Forms 10-K, 10-Q, 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings provide detailed information on Colgate-Palmolive’s Oral Care, Personal Care, Home Care and Pet Nutrition businesses, its financial performance and its capital structure.
Colgate-Palmolive’s 8-K filings illustrate how the company uses SEC reports to communicate material events. For example, an 8-K dated November 10, 2025 describes the execution of an underwriting agreement and the issuance of €600,000,000 of 3.250% Senior Notes due 2035 under an automatic shelf registration statement. Other 8-Ks furnish quarterly earnings press releases and explain multi-year productivity initiatives, such as the Strategic Growth and Productivity Program designed to support the company’s 2030 strategy by aligning its organizational structure, optimizing its global supply chain and streamlining overhead.
Filings also list Colgate-Palmolive’s securities registered under Section 12(b) of the Exchange Act, including its common stock (ticker CL) and various series of notes traded on the New York Stock Exchange. Through proxy statements and other periodic reports, investors can review topics such as segment reporting, non-GAAP financial measures like Base Business and organic sales growth, and risk factor disclosures.
On Stock Titan, these SEC documents are updated from EDGAR and paired with AI-powered summaries that highlight key points, such as changes in capital allocation, new debt offerings, productivity program charges or revisions to guidance. Users can quickly scan filings for material information while retaining access to the complete original documents for deeper analysis.
Colgate-Palmolive Chief Growth Officer Hazlin John exercised stock options for 20,989 shares of common stock at $76.41 per share on February 10, 2026, then sold 20,989 shares at a weighted average price of $94.2499 per share. A portion of the sale proceeds was delivered to the company to pay the option exercise price and related tax withholding. After these transactions, John directly owned 17,645 shares and indirectly held 5,452 shares through the issuer's 401(k) plan trustee.
A shareholder associated with Colgate-Palmolive Company has filed a notice to sell 35,000 shares of common stock on the NYSE through Merrill Lynch. The planned sale has an aggregate market value of $3,311,325.26.
The shares were acquired on 02/11/2026 through the exercise of employee stock options via a broker-assisted cashless exercise, with payment also dated 02/11/2026. Colgate-Palmolive had 806,064,942 shares outstanding of common stock at the time referenced.
Colgate-Palmolive executive Malcolm Gregory reported an employee stock option exercise and related share sale. On February 6, 2026, he exercised options for 12,747 shares of common stock at $76.41 per share under the company’s incentive compensation plan.
That same day, he sold 12,747 shares of Colgate-Palmolive common stock in market transactions at a weighted average price of $94.9103 per share, with individual trades ranging from $94.79 to $95.01. After these transactions, he directly owned 11,879 shares and held an additional 8,554 shares indirectly through the issuer’s 401(k) plan trustee.
Colgate-Palmolive common stock holder plans to sell shares under Rule 144. A holder has filed a notice to sell 20,989 shares of Colgate-Palmolive common stock through Merrill Lynch on or about 02/10/2026, with an indicated aggregate market value of $1,978,210.97 on the NYSE.
The shares were acquired on 02/10/2026 from Colgate-Palmolive via an employee stock option exercise structured as a broker-assisted cashless exercise. Colgate-Palmolive had 806,064,942 shares outstanding at the time referenced, providing context for the relative size of this planned sale.
Colgate-Palmolive Chief Human Resources Officer Sally Massey reported an option exercise and related share sale. On February 5, 2026, she exercised stock options for 15,851 shares of common stock at $76.41 per share, awarded under the company’s incentive compensation plan.
That same day, she sold 15,851 shares of common stock at a weighted average price of $95.0279, with part of the proceeds used to pay the option exercise price and related tax withholding. After these transactions, she directly owned 13,751 shares of Colgate-Palmolive common stock and held an additional 8,111 shares indirectly through the issuer’s 401(k) plan trustee.
Colgate-Palmolive’s Chief Financial Officer, Stanley J. Sutula III, exercised stock options and sold shares in a planned transaction. On February 4, 2026, he exercised 97,843 stock options at an exercise price of $81.78 per share under the company’s incentive compensation plan.
That same day, he sold 97,843 shares of common stock at a weighted average price of $94.2662 per share, with a portion of the proceeds delivered to Colgate-Palmolive to cover the option exercise price and related tax withholding. After these transactions, he directly owned 55,310 common shares and indirectly held 328 shares through the issuer’s 401(k) plan trustee.
Colgate-Palmolive’s Chief Legal Officer and Secretary, Jennifer Daniels, reported an option exercise and share sale. On February 4, 2026, she exercised stock options for 22,000 shares of common stock at
That same day, she sold 22,000 shares of common stock at a weighted average price of
Colgate-Palmolive Chairman, President & CEO Noel R. Wallace reported a sale of common stock. On February 4, 2026, he sold 45,568 shares of Colgate-Palmolive common stock at a weighted average price of $93.9145 per share, in multiple transactions within a stated price range.
After this sale, Wallace directly owned 293,188 common shares. He also reported indirect ownership of 54,281 shares through the issuer's 401(k) plan trustee, 52,000 shares through a spouse trust, and 335 shares through another trust.
Colgate-Palmolive (CL) has a planned Rule 144 stock sale by a shareholder following an option exercise. The holder intends to sell 22,000 shares of Colgate-Palmolive common stock through Merrill Lynch on or around 02/04/2026 on the NYSE, with an aggregate market value of $2,075,398.18.
The shares were acquired the same day by exercising employee stock options via a broker-assisted cashless exercise. Colgate-Palmolive had 806,064,942 common shares outstanding, providing context for the size of this proposed sale.
Colgate-Palmolive reported a planned sale of 45,568 shares of its common stock under a Rule 144 notice, with an aggregate market value of $4,279,497.44. The shares are to be sold through Merrill Lynch on the NYSE around 02/04/2026.
The securities were acquired through vesting of performance share unit awards from Colgate-Palmolive in February and September 2024, granted as part of the issuer’s equity compensation plan.